Therapeutic itinerary

trajectory for resolution of adverse events of patients using warfarin in Southern Brazil

Autores

  • Christiane Colet Universidade Regional do Noroeste do Estado do Rio Grande do Sul. Departamento de Ciências da Vida
  • Tânia Alves Amador Universidade Federal do Rio Grande do Sul. Faculdade de Farmácia
  • Isabela Heineck Universidade Federal do Rio Grande do Sul. Faculdade de Farmácia

DOI:

https://doi.org/10.1590/s2175-97902018000317738

Palavras-chave:

Warfarin/adverse drug, Cohort studies, Health services accessibility, Reaction, Brazil

Resumo

Warfarin is the most used anticoagulant in primary health care. Due to the narrow therapeutic index, its users are more susceptible to adverse events. The objective of this study was to describe the itinerary of the public health sector patients for resolution of adverse events related to warfarin. It is a prospective open cohort, held for a period of 18 months with warfarin users of the Brazilian public health system. Data were collected by monthly interviews and from patient records. Results: Sixty nine patients were interviewed, 64 of them completed monitoring and five died. Bleeding and venous thromboembolism were more frequent in patients starting treatment. It was observed that when adverse events have occurred, in most cases the patient held self-care at home (57%). During the follow-up, five patients were hospitalized for bleeding. Approximately half of the patients did not present their INR exams to the doctor. Conclusions: This study demonstrates weaknesses in caring for these patients and the need to accompany them, aiming to standardize and guide the itinerary of the anticoagulated patient to solve their problems and improve safety in drug treatment, with less cost to the public health system.

Downloads

Os dados de download ainda não estão disponíveis.

Downloads

Publicado

2018-11-29

Edição

Seção

Artigos

Como Citar

Therapeutic itinerary: trajectory for resolution of adverse events of patients using warfarin in Southern Brazil. (2018). Brazilian Journal of Pharmaceutical Sciences, 54(3), e17738. https://doi.org/10.1590/s2175-97902018000317738